



## Clinical trial results:

### A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

#### Summary

EudraCT number	2016-002579-83
Trial protocol	ES HU FR PL
Global end of trial date	26 September 2019

#### Results information

Result version number	v1 (current)
This version publication date	11 October 2020
First version publication date	11 October 2020

#### Trial information

##### Trial identification

Sponsor protocol code	CR108256
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03023423
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 US Highway Route 202 South, Raritan, United States, NJ 08869
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 September 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 September 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to compare the overall response rate (ORR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included adverse events, routine clinical laboratory tests (hematology, chemistry, urinalysis), vital signs (temperature, pulse/heart rate, and blood pressure), physical examination, infusion related reactions and electrocardiogram (ECG).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 49
Country: Number of subjects enrolled	France: 16
Country: Number of subjects enrolled	Hungary: 15
Country: Number of subjects enrolled	United States: 19
Worldwide total number of subjects	99
EEA total number of subjects	80

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	53
From 65 to 84 years	45
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 100 subjects were enrolled in the study (7 in phase 1b [safety run-in phase], and 93 in Phase 2 [randomized phase]). Among them, 99 subjects (7 in phase 1b [safety run-in phase], and 92 in phase 2 [randomized phase]) were randomized as 1 subject was randomized after the clinical cutoff date (17-May-2018).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Safety Run-in Phase: Daratumumab + Atezolizumab

Arm description:

Subjects received daratumumab (Dara) 16 milligram per kilogram (mg/kg) intravenously (IV) weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab (Atezo) IV at a dose of 1200 milligram (mg) on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Arm type	Experimental
Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received daratumumab 16 mg/kg intravenously weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received atezolizumab (Atezo) IV at a dose of 12 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

<b>Arm title</b>	Randomized Phase: Atezolizumab
------------------	--------------------------------

Arm description:

Subjects received atezolizumab IV at a dose of 1200 milligram (mg) on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received atezolizumab IV at a dose of 1200 mg on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

<b>Arm title</b>	Randomized Phase: Daratumumab + Atezolizumab
------------------	----------------------------------------------

**Arm description:**

Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Arm type	Experimental
Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Number of subjects in period 1	Safety Run-in Phase: Daratumumab + Atezolizumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab
Started	7	46	46
Treated	7	44	44
Crossover from Atezo to Dara + Atezo	0 <sup>[1]</sup>	8 <sup>[2]</sup>	0 <sup>[3]</sup>
Completed	2	32	24
Not completed	5	14	22
Death	5	12	20
Unspecified	-	2	2

**Notes:**

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects crossed over from Atezo arm to Dara + Atezo arm.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only 8 subjects crossed over from Atezo arm to Dara + Atezo arm.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects crossed over from Atezo arm to Dara + Atezo arm.

## Baseline characteristics

### Reporting groups

Reporting group title	Safety Run-in Phase: Daratumumab + Atezolizumab
Reporting group description:	
Subjects received daratumumab (Dara) 16 milligram per kilogram (mg/kg) intravenously (IV) weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab (Atezo) IV at a dose of 1200 milligram (mg) on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.	
Reporting group title	Randomized Phase: Atezolizumab
Reporting group description:	
Subjects received atezolizumab IV at a dose of 1200 milligram (mg) on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.	
Reporting group title	Randomized Phase: Daratumumab + Atezolizumab
Reporting group description:	
Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.	

Reporting group values	Safety Run-in Phase: Daratumumab + Atezolizumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab
Number of subjects	7	46	46
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	29	21
From 65 to 84 years	4	17	25
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	61	61.7	63.2
standard deviation	± 9.73	± 10.05	± 10.76
Title for Gender Units: subjects			
Female	3	18	8
Male	4	28	38
Race/Ethnicity Units: Subjects			
Other	0	11	6
White Non-Hispanic	7	35	40
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0

White	7	35	41
More than one race	0	0	0
Unknown or Not Reported	0	11	5
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	7	36	40
Unknown or Not Reported	0	9	6
Eastern Cooperative Oncology Group (ECOG) Performance Status			
ECOG performance status was used to evaluate the effect of the disease status on the activities of daily living. ECOG performance status was determined by ECOG 5-point scale: 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.			
Units: Subjects			
ECOG Score 0	3	19	12
ECOG Score 1	4	27	33
ECOG Score 2	0	0	1
Time from initial diagnosis			
Time from initial diagnosis is defined as the time from the initial diagnosis of non-small cell lung cancer (NSCLC) to the first dosing date or randomization date (if first dosing date is missing).			
Units: Months			
arithmetic mean	10.3	18.8	17.6
standard deviation	± 9.29	± 20.89	± 14.17

<b>Reporting group values</b>	Total		
Number of subjects	99		
Title for AgeCategorical			
Units: subjects			
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	53		
From 65 to 84 years	46		
85 years and over	0		
Title for AgeContinuous			
Units: years			
arithmetic mean			
standard deviation	-		
Title for Gender			
Units: subjects			
Female	29		
Male	70		
Race/Ethnicity			
Units: Subjects			
Other	17		
White Non-Hispanic	82		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	0		
Native Hawaiian or Other Pacific Islander	0		



Black or African American	0		
White	83		
More than one race	0		
Unknown or Not Reported	16		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1		
Not Hispanic or Latino	83		
Unknown or Not Reported	15		
Eastern Cooperative Oncology Group (ECOG) Performance Status			
ECOG performance status was used to evaluate the effect of the disease status on the activities of daily living. ECOG performance status was determined by ECOG 5-point scale: 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.			
Units: Subjects			
ECOG Score 0	34		
ECOG Score 1	64		
ECOG Score 2	1		
Time from initial diagnosis			
Time from initial diagnosis is defined as the time from the initial diagnosis of non-small cell lung cancer (NSCLC) to the first dosing date or randomization date (if first dosing date is missing).			
Units: Months			
arithmetic mean			
standard deviation	-		

## End points

### End points reporting groups

Reporting group title	Safety Run-in Phase: Daratumumab + Atezolizumab
-----------------------	-------------------------------------------------

#### Reporting group description:

Subjects received daratumumab (Dara) 16 milligram per kilogram (mg/kg) intravenously (IV) weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab (Atezo) IV at a dose of 1200 milligram (mg) on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Reporting group title	Randomized Phase: Atezolizumab
-----------------------	--------------------------------

#### Reporting group description:

Subjects received atezolizumab IV at a dose of 1200 milligram (mg) on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Reporting group title	Randomized Phase: Daratumumab + Atezolizumab
-----------------------	----------------------------------------------

#### Reporting group description:

Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Subject analysis set title	Safety Run-in: Atezolizumab + Daratumumab
----------------------------	-------------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Subjects received daratumumab 16 milligram per kilogram (mg/kg) Intravenously (IV) weekly for first 3 cycles and every 3 weeks for all cycles thereafter along with atezolizumab IV at a dose of 1200 milligram (mg) on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter.

Subject analysis set title	Randomized Phase: Atezolizumab
----------------------------	--------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Subjects received atezolizumab IV at a dose of 1200 milligram (mg) on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Subject analysis set title	Randomized Phase: Daratumumab + Atezolizumab
----------------------------	----------------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Subject analysis set title	Randomized Phase: Atezo Crossed Over to Dara + Atezo
----------------------------	------------------------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Subjects who crossed over from Atezolizumab arm (Randomized Phase) to Daratumumab + Atezolizumab arm (Randomized Phase) received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol defined treatment discontinuation criteria.

### Primary: Percentage of Subjects with Overall Response Rate (ORR)

End point title	Percentage of Subjects with Overall Response Rate (ORR)
-----------------	---------------------------------------------------------

#### End point description:

ORR was defined as the percentage of subjects with partial response (PR) or complete response (CR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Criteria for CR: Disappearance of all target lesions; all lymph nodes must be of non-pathological in size (less than [ $<$ ]10 millimeter [mm] short axis; normalization of tumor marker level. Criteria for PR: greater than or equal to ( $\geq$ )30 percent (%) decrease in sum of the diameter of all target lesions compared with baseline, in absence of new

lesions or unequivocal progression of non-target lesions. Overall Response (OR) = CR + PR. The endpoint was planned to be reported for subjects based on their initial assignment to Randomized Phase: Atezolizumab'. Intent-to-treat (ITT) analysis set included all subjects who had entered the Randomized phase of the study.

End point type	Primary
End point timeframe:	
Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	46		
Units: Percentage of Subjects				
number (confidence interval 95%)	13.0 (4.9 to 26.3)	4.3 (0.5 to 14.8)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Randomized Phase: Atezolizumab v Randomized Phase: Daratumumab + Atezolizumab
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.03
upper limit	1.92

## Secondary: Number of Subjects with Adverse Events

End point title	Number of Subjects with Adverse Events
End point description:	
An adverse event (AE) is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Crossover subjects were counted twice (in 'Randomized Phase: Atezo arm' and in 'Randomized Phase: Atezo Crossed Over to Dara + Atezo') for safety analysis. For cross-over subjects, AEs after initiation of cross-over treatment were summarized separately in the crossover arm, however, AEs occurred before crossover treatment were included in 'Randomized Phase: Atezolizumab arm'. Safety analysis set included all subjects who had received at least 1 administration of any study medication.	
End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Safety Run-in: Atezolizumab + Daratumumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab	Randomized Phase: Atezo Crossed Over to Dara + Atezo
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	44	44	8
Units: Subjects	7	42	44	8

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DoR)

End point title	Duration of Response (DoR)
End point description: DOR: Duration from date of initial documentation of disease response to date of first documented evidence of recurrence/PD/death, whichever occurred first. PD: Sum of diameters increased by $\geq 20\%$ , $\geq 5$ mm from nadir. Subjects with measurable disease: Unequivocal progression (non-target disease, overall level of substantial worsening that merits discontinuation of therapy). Subjects without measurable disease: Unequivocal progression (non-target disease, increase in tumor burden comparable to increase required for PD of measurable disease). Endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. ITT set: subjects who had entered Randomized phase of study. N (number of subjects analyzed): number of subjects who were evaluable for this endpoint. 99999: lower/upper limit of 95% CI were not estimable due: lesser number of subjects with events.	
End point type	Secondary
End point timeframe: Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6	2		
Units: Months				
median (confidence interval 95%)	5.8 (2.2 to 5.8)	2.9 (-99999 to 99999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Clinical Benefit Rate

End point title	Clinical Benefit Rate
End point description:	
Clinical benefit rate was defined as percentage of subjects who achieved disease control (CR, PR, or SD). RECIST 1.1 Criteria for CR: Disappearance of all target lesions; all lymph nodes of non-pathological in size (<10 millimeter [mm] short axis); normalization of tumor marker level. Criteria for PR: $\geq 30\%$ decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Criteria for SD: $< 30\%$ decrease in sum of diameters of all target lesions compared with baseline and $< 20\%$ increase compared with nadir, in absence of new lesions or unequivocal progression of nontarget lesions. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. ITT analysis set included all subjects who had entered the Randomized phase of the study.	
End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	46		
Units: Percentage of Subjects				
number (confidence interval 95%)	43.5 (28.9 to 58.9)	52.2 (36.9 to 67.1)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS)
End point description:	
PFS was defined as the duration from the date of randomization until the first documented disease progression (PD) or death, whichever occurred first. PD: Sum of diameters increased by $\geq 20\%$ and $\geq 5$ millimeter (mm) from nadir (including baseline if it was smallest sum). Subjects with measurable disease: for "unequivocal progression" based on non-target disease, overall level of substantial worsening that merits discontinuation of therapy (if target disease was stable disease [SD]/PR). Subjects without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden comparable to increase required for PD of measurable disease. Appearance of 1/ more new lesions or unequivocal progression of non-target lesion was also considered as PD. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. ITT analysis set included all subjects who had entered the Randomized phase of the study.	
End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	46		
Units: Months				
median (confidence interval 95%)	1.48 (1.38 to 2.76)	1.68 (1.41 to 2.79)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
Overall Survival was defined as the duration from the date of randomization to the date of subject's death due to any cause. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. ITT analysis set included all subjects who had entered the Randomized phase of the study. Here 99999, signifies that the upper limit of 95% Confidence Interval (CI) was not estimable due to lesser number of events.	
End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	46		
Units: Months				
median (confidence interval 95%)	99999 (7.43 to 99999)	7.13 (3.52 to 99999)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Daratumumab Serum Concentration

End point title	Daratumumab Serum Concentration
End point description:	
Daratumumab serum concentrations were reported. Each cycle was of 21-days. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. Pharmacokinetic (PK)-evaluable analysis set included all subjects who had received at least 1 dose of daratumumab or atezolizumab and had at least 1 postinfusion sample collected. Here 'n' (number of subjects analyzed) signifies those subjects who were evaluable for this endpoint at a given time point. Here 99999, signifies that Standard Deviation could not be calculated for a single subject.	

End point type	Secondary
End point timeframe:	
Cycle 1 Day 1 (C1D1):predose and postdose; C2D1 and C3D1:predose; C3D15: predose and postdose; C4D1: predose and postdose; C8D1: predose and postdose; C12D1: predose; end of treatment (37 days after last dose); and post last dose (up to 1.5 years)	

End point values	Safety Run-in: Atezolizumab + Daratumumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	43		
Units: Microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Predose (n=7, 43)	0.00 (± 0.000)	0.00 (± 0.000)		
Cycle 1 Day 1 Postdose (n=6, 38)	417.13 (± 141.626)	296.12 (± 85.660)		
Cycle 2 Day 1 Predose (n=4, 35)	393.95 (± 139.480)	278.42 (± 89.340)		
Cycle 3 Day 1 Predose (n=3, 26)	740.17 (± 99.515)	487.65 (± 124.935)		
Cycle 3 Day 15 Predose (n=4, 24)	843.22 (± 156.792)	552.79 (± 180.549)		
Cycle 3 Day 15 Postdose (n=4, 23)	1088.73 (± 282.349)	827.72 (± 266.085)		
Cycle 4 Day 1 Predose (n=3, 22)	899.90 (± 123.305)	574.81 (± 181.193)		
Cycle 4 Day 1 Postdose (n=3, 21)	1416.40 (± 353.415)	856.30 (± 244.698)		
Cycle 8 Day 1 Predose (n=1, 8)	254.87 (± 99999)	288.84 (± 177.187)		
Cycle 8 Day 1 Postdose (n=1, 8)	824.64 (± 99999)	617.21 (± 239.962)		
Cycle 12 Day 1 Predose (n=0, 2)	99999 (± 99999)	260.21 (± 17.163)		
End of Treatment (n=3, 13)	405.14 (± 242.189)	187.75 (± 110.531)		
Post Last Dose (n=2, 5)	41.84 (± 23.082)	112.63 (± 115.727)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Atezolizumab Serum Concentration

End point title	Atezolizumab Serum Concentration
End point description:	
Atezolizumab serum concentrations were reported. Each cycle was of 21-days. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. PK-evaluable analysis set: all subjects who received at least 1 dose of daratumumab/atezolizumab and had at least 1 postinfusion sample collected. Here N (number of subjects analyzed): subjects evaluable for this endpoint, and n (number of subjects analyzed): subjects evaluable for this endpoint at given timepoint. Here 99999, signifies that the standard deviation could	

not be calculated for a single subject.

End point type	Secondary
End point timeframe:	
C1D1:predose and postdose; C1D2:predose and postdose; C2D1, C3D1:predose; C3D15:predose and postdose; C4D1:predose and postdose; C8D1:predose and postdose; C12D1:predose; end of treatment (37 days after last dose); and post last dose (up to 1.5 years)	

End point values	Safety Run-in: Atezolizumab + Daratumumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	7	39	39	
Units: Microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Predose (n=0,37,13)	99999 (± 99999)	0.00 (± 0.000)	0.00 (± 0.000)	
Cycle 1 Day 1 Postdose (n=0,37,3)	99999 (± 99999)	396.51 (± 103.196)	440.00 (± 93.145)	
Cycle 1 Day 2 Predose (n=7,0,24)	0.00 (± 0.000)	99999 (± 99999)	0.00 (± 0.000)	
Cycle 1 Day 2 Postdose (n=7,0,34)	362.14 (± 43.434)	99999 (± 99999)	343.82 (± 135.476)	
Cycle 2 Day 1 Predose (n=5,30,20)	91.16 (± 15.305)	78.85 (± 30.575)	81.90 (± 20.021)	
Cycle 3 Day 1 Predose (n=2,21,17)	176.50 (± 33.234)	117.61 (± 33.227)	123.51 (± 31.882)	
Cycle 4 Day 1 Predose (n=2,18,12)	166.50 (± 37.477)	145.64 (± 37.323)	157.79 (± 37.819)	
Cycle 4 Day 1 Postdose (n=4,17,18)	612.25 (± 81.578)	539.24 (± 116.291)	482.33 (± 139.879)	
Cycle 8 Day 1 Predose (n=0,6,0)	99999 (± 99999)	158.23 (± 77.778)	99999 (± 99999)	
Cycle 8 Day 1 Postdose (n=0,8,4)	99999 (± 99999)	527.50 (± 213.492)	515.25 (± 214.177)	
Cycle 12 Day 1 Predose (n=0,1,1)	99999 (± 99999)	183.00 (± 99999)	248.00 (± 99999)	
End of Treatment (n=3,11,12)	136.43 (± 73.002)	129.55 (± 79.720)	141.62 (± 71.756)	
Post Last Dose (n=1,2,2)	33.10 (± 99999)	13.17 (± 8.386)	115.10 (± 146.937)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Anti-Daratumumab Antibodies

End point title	Number of Subjects with Anti-Daratumumab Antibodies
-----------------	-----------------------------------------------------

End point description:

Number of subjects with antibodies to daratumumab (tested using a validated immunoassay method) were reported. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. The immunogenicity-evaluable analysis set included all subjects who received at least 1 dose of atezolizumab or daratumumab and had appropriate samples for detection of



antibodies to atezolizumab or daratumumab. Here 'N' (number of subjects analyzed) signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	37		
Units: Subjects				
number (not applicable)	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Anti-Atezolizumab Antibodies

End point title	Number of Subjects with Anti-Atezolizumab Antibodies
End point description:	
Number of subjects with antibodies to atezolizumab (tested using a validated immunoassay method) were reported. The endpoint was planned to be reported for subjects based on their initial assignment to 'Randomized Phase: Atezolizumab'. The immunogenicity-evaluable analysis set included all subjects who received at least 1 dose of atezolizumab or daratumumab and had appropriate samples for detection of antibodies to atezolizumab or daratumumab.	
End point type	Secondary
End point timeframe:	
Up to 1.5 years	

End point values	Safety Run-in: Atezolizumab + Daratumumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	7	39	38	
Units: Subjects	0	6	5	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 1.5 years

Adverse event reporting additional description:

Safety analysis set=subjects who received at least 1 administration of any study drug. Crossover subjects were counted twice (in 'Randomized Phase:Atezo arm' and 'Randomized Phase: Atezo Crossed Over to Dara+Atezo'). AEs summarized separately in crossover arm and occurred before crossover treatment were included in 'Randomized Phase: Atezolizumab'.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

### Reporting groups

Reporting group title	Safety Run-in Phase: Daratumumab + Atezolizumab
-----------------------	-------------------------------------------------

Reporting group description:

Subjects received daratumumab (Dara) 16 milligram per kilogram (mg/kg) intravenously (IV) weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab (Atezo) IV at a dose of 1200 milligram (mg) on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Reporting group title	Randomized Phase: Atezolizumab
-----------------------	--------------------------------

Reporting group description:

Subjects received atezolizumab IV at a dose of 1200 milligram (mg) on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Reporting group title	Randomized Phase: Daratumumab + Atezolizumab
-----------------------	----------------------------------------------

Reporting group description:

Subjects received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Reporting group title	Randomized Phase: Atezo Crossed Over to Dara + Atezo
-----------------------	------------------------------------------------------

Reporting group description:

Subjects who crossed over from Atezolizumab arm (Randomized Phase) to Daratumumab + Atezolizumab arm (Randomized Phase) received daratumumab 16 mg/kg IV weekly on Days 1, 8, and 15 for first 3 cycles and then on Day 1 of each 21-day cycle thereafter along with atezolizumab IV at a dose of 1200 mg on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter until disease progression, unacceptable toxicity or other protocol-defined treatment discontinuation criteria.

Serious adverse events	Safety Run-in Phase: Daratumumab + Atezolizumab	Randomized Phase: Atezolizumab	Randomized Phase: Daratumumab + Atezolizumab
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 7 (57.14%)	15 / 44 (34.09%)	21 / 44 (47.73%)
number of deaths (all causes)	2	9	11
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			

Femur Fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardio-Respiratory Arrest			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Myocardial Infarction			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pericardial Effusion			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular Accident			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Transient Ischaemic Attack			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vocal Cord Paralysis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General Physical Health Deterioration			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Non-Cardiac Chest Pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden Death			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal disorders			
Abdominal Pain			

subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal Haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchial Fistula			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial Obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	6 / 44 (13.64%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Haemoptysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Painful Respiration			

subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural Effusion			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Embolism			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory Failure			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Back Pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in Extremity			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral Infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	3 / 44 (6.82%)	3 / 44 (6.82%)
occurrences causally related to treatment / all	0 / 0	1 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Respiratory Tract Infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	3 / 44 (6.82%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Randomized Phase: Atezo Crossed Over to Dara + Atezo		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 8 (37.50%)		
number of deaths (all causes)	3		
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Femur Fracture			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-Respiratory Arrest			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial Infarction			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial Effusion			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular Accident			



subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient Ischaemic Attack			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vocal Cord Paralysis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General Physical Health Deterioration			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Sudden Death			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal Haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial Fistula			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchial Obstruction			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences causally related to treatment / all	2 / 5		
deaths causally related to treatment / all	1 / 2		

Haemoptysis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Painful Respiration			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural Effusion			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary Embolism			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory Failure			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain in Extremity			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral Infection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory Tract Infection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Superinfection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Urinary Tract Infection			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	<b>Safety Run-in Phase: Daratumumab + Atezolizumab</b>	<b>Randomized Phase: Atezolizumab</b>	<b>Randomized Phase: Daratumumab + Atezolizumab</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	41 / 44 (93.18%)	41 / 44 (93.18%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	2
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	1	0	2
Hypertension			
subjects affected / exposed	4 / 7 (57.14%)	0 / 44 (0.00%)	4 / 44 (9.09%)
occurrences (all)	7	0	5
Hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Venous Thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 7 (42.86%)	15 / 44 (34.09%)	14 / 44 (31.82%)
occurrences (all)	4	21	23

Chest Discomfort			
subjects affected / exposed	2 / 7 (28.57%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	2	0	2
Chest Pain			
subjects affected / exposed	0 / 7 (0.00%)	3 / 44 (6.82%)	3 / 44 (6.82%)
occurrences (all)	0	3	3
Chills			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	3 / 44 (6.82%)
occurrences (all)	1	0	3
Fatigue			
subjects affected / exposed	3 / 7 (42.86%)	7 / 44 (15.91%)	9 / 44 (20.45%)
occurrences (all)	3	11	11
General Physical Health Deterioration			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Hypothermia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	2
Localised Oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	1	0	0
Mucosal Inflammation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	2
Oedema Peripheral			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	2 / 44 (4.55%)
occurrences (all)	0	2	2
Pain			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences (all)	0	2	0

Pyrexia subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 3	5 / 44 (11.36%) 5	4 / 44 (9.09%) 5
Secretion Discharge subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 44 (0.00%) 0	1 / 44 (2.27%) 1
Temperature Intolerance subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0
Immune system disorders Drug Hypersensitivity subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 44 (2.27%) 1	1 / 44 (2.27%) 1
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 44 (0.00%) 0	4 / 44 (9.09%) 4
Reproductive system and breast disorders Gynaecomastia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Aspiration subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 44 (0.00%) 0	0 / 44 (0.00%) 0
Bronchospasm subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 44 (0.00%) 0	3 / 44 (6.82%) 4
Cough subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	10 / 44 (22.73%) 13	16 / 44 (36.36%) 19
Dry Throat subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 44 (0.00%) 0	0 / 44 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 44 (0.00%) 0	1 / 44 (2.27%) 1

Dyspnoea			
subjects affected / exposed	5 / 7 (71.43%)	9 / 44 (20.45%)	13 / 44 (29.55%)
occurrences (all)	5	10	18
Dyspnoea Exertional			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Haemoptysis			
subjects affected / exposed	0 / 7 (0.00%)	5 / 44 (11.36%)	5 / 44 (11.36%)
occurrences (all)	0	6	5
Laryngeal Oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Nasal Congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Oropharyngeal Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Pleural Effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Pleurisy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Pleuritic Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Pneumothorax			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Productive Cough			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	2



Rhinorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sneezing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Throat Irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	4 / 44 (9.09%)
occurrences (all)	0	0	5
Throat Tightness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Upper-Airway Cough Syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Depression			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	1	0	1
Insomnia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	1	0	1
Nervousness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sleep Disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	1 / 44 (2.27%)
occurrences (all)	0	2	1
Aspartate Aminotransferase Increased			

subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	2 / 44 (4.55%)
occurrences (all)	0	2	3
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	3
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Eastern Cooperative Oncology Group Performance Status Worsened			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	2
Lipase Increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	4
Oxygen Saturation Decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Weight Decreased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	3 / 44 (6.82%)
occurrences (all)	0	1	3
Weight Increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Buttock Injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			

Pericardial Effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sinus Bradycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sinus Tachycardia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	2	0	2
Tachycardia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	1	1	1
Ventricular Extrasystoles			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Aphonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	2 / 7 (28.57%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences (all)	2	1	2
Dysgeusia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	3 / 7 (42.86%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences (all)	3	2	0
Hypokinesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	3 / 44 (6.82%)	2 / 44 (4.55%)
occurrences (all)	0	4	2
Peripheral Sensory Neuropathy			

subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences (all)	0	2	0
Seizure			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Somnolence			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 7 (14.29%)	6 / 44 (13.64%)	7 / 44 (15.91%)
occurrences (all)	1	10	11
Deficiency Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Leukopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences (all)	0	1	3
Thrombocytopenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences (all)	0	2	2
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Dry Eye			

subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	1	0	0
Eye Irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Vision Blurred			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Visual Acuity Reduced			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Abdominal Pain			
subjects affected / exposed	2 / 7 (28.57%)	0 / 44 (0.00%)	6 / 44 (13.64%)
occurrences (all)	2	0	6
Abdominal Pain Upper			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences (all)	0	2	0
Constipation			
subjects affected / exposed	2 / 7 (28.57%)	5 / 44 (11.36%)	4 / 44 (9.09%)
occurrences (all)	2	6	7
Diarrhoea			
subjects affected / exposed	1 / 7 (14.29%)	4 / 44 (9.09%)	4 / 44 (9.09%)
occurrences (all)	2	5	4
Dry Mouth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	3 / 44 (6.82%)
occurrences (all)	0	1	3

Flatulence			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	1
Gastroesophageal Reflux Disease			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	3 / 7 (42.86%)	8 / 44 (18.18%)	7 / 44 (15.91%)
occurrences (all)	4	9	9
Odynophagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	1	0	2
Toothache			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	1 / 7 (14.29%)	3 / 44 (6.82%)	6 / 44 (13.64%)
occurrences (all)	1	3	7
Skin and subcutaneous tissue disorders			
Dermatitis Acneiform			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Dry Skin			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	1
Eczema			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Erythema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	3
Hair Disorder			

subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Night Sweats			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 7 (0.00%)	4 / 44 (9.09%)	0 / 44 (0.00%)
occurrences (all)	0	5	0
Rash			
subjects affected / exposed	2 / 7 (28.57%)	2 / 44 (4.55%)	3 / 44 (6.82%)
occurrences (all)	2	2	4
Rash Maculo-Papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Rash Papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Rash Pruritic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Skin Lesion			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	1 / 7 (14.29%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	1	0	0
Bladder Spasm			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0

Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	2
Pollakiuria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Renal Colic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Renal Failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Renal Vein Thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Urinary Retention			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 7 (0.00%)	3 / 44 (6.82%)	0 / 44 (0.00%)
occurrences (all)	0	3	0
Hypothyroidism			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 7 (14.29%)	8 / 44 (18.18%)	1 / 44 (2.27%)
occurrences (all)	2	11	1
Arthritis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Back Pain			
subjects affected / exposed	0 / 7 (0.00%)	3 / 44 (6.82%)	3 / 44 (6.82%)
occurrences (all)	0	5	3
Groin Pain			



subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Muscle Contracture			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Muscle Spasms			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	1 / 44 (2.27%)
occurrences (all)	0	1	1
Muscular Weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Musculoskeletal Chest Pain			
subjects affected / exposed	1 / 7 (14.29%)	2 / 44 (4.55%)	1 / 44 (2.27%)
occurrences (all)	1	2	1
Musculoskeletal Discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal Pain			
subjects affected / exposed	0 / 7 (0.00%)	2 / 44 (4.55%)	0 / 44 (0.00%)
occurrences (all)	0	2	0
Myalgia			
subjects affected / exposed	1 / 7 (14.29%)	5 / 44 (11.36%)	1 / 44 (2.27%)
occurrences (all)	1	11	1
Neck Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Pain in Extremity			
subjects affected / exposed	1 / 7 (14.29%)	4 / 44 (9.09%)	4 / 44 (9.09%)
occurrences (all)	1	5	5
Spinal Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1

Furuncle			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	2 / 44 (4.55%)
occurrences (all)	0	0	4
Oral Herpes			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Respiratory Tract Infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	5 / 44 (11.36%)
occurrences (all)	0	0	15
Rhinitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1
Tooth Infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	2	0
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	1	0
Urinary Tract Infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences (all)	0	1	2
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	2 / 7 (28.57%)	7 / 44 (15.91%)	11 / 44 (25.00%)
occurrences (all)	2	10	16
Dehydration			

subjects affected / exposed	2 / 7 (28.57%)	0 / 44 (0.00%)	1 / 44 (2.27%)
occurrences (all)	2	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	3 / 44 (6.82%)
occurrences (all)	0	0	3
Hypoalbuminaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	0	2	0
Hypocalcaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 44 (2.27%)	2 / 44 (4.55%)
occurrences (all)	0	1	2
Hypokalaemia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 44 (2.27%)	0 / 44 (0.00%)
occurrences (all)	1	1	0
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 44 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Randomized Phase: Atezo Crossed Over to Dara + Atezo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypotension			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Thrombosis			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Venous Thrombosis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Chest Discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Chest Pain			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Chills			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	4		
General Physical Health Deterioration			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypothermia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Localised Oedema			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Mucosal Inflammation			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Non-Cardiac Chest Pain			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Oedema Peripheral			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Secretion Discharge			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Temperature Intolerance			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Drug Hypersensitivity			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypersensitivity			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Gynaecomastia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Bronchospasm			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	3 / 8 (37.50%)		
occurrences (all)	4		
Dry Throat			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dysphonia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dyspnoea Exertional			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Haemoptysis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Laryngeal Oedema			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Nasal Congestion			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	2		
Oropharyngeal Pain			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Pleural Effusion			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pleurisy			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pleuritic Pain			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pneumonitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pneumothorax			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Productive Cough			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sneezing			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Throat Irritation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Throat Tightness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Upper-Airway Cough Syndrome			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Nervousness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sleep Disorder			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eastern Cooperative Oncology Group Performance Status Worsened			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Lipase Increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Oxygen Saturation Decreased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Weight Decreased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		



Weight Increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Injury, poisoning and procedural complications Buttock Injury subjects affected / exposed occurrences (all)  Fall subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0		
Cardiac disorders Pericardial Effusion subjects affected / exposed occurrences (all)  Sinus Bradycardia subjects affected / exposed occurrences (all)  Sinus Tachycardia subjects affected / exposed occurrences (all)  Tachycardia subjects affected / exposed occurrences (all)  Ventricular Extrasystoles subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  1 / 8 (12.50%) 1  0 / 8 (0.00%) 0  0 / 8 (0.00%) 0		
Nervous system disorders Aphonia subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)  Dysgeusia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  1 / 8 (12.50%) 1  0 / 8 (0.00%) 0		

Headache			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Hypokinesia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Peripheral Sensory Neuropathy			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Seizure			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Deficiency Anaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Lymphopenia			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dry Eye			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eye Irritation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vision Blurred			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Visual Acuity Reduced			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Abdominal Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Abdominal Pain Upper			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Colitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Constipation			

subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	3		
Diarrhoea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dry Mouth			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Gastrooesophageal Reflux Disease			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Odynophagia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Dermatitis Acneiform			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Dry Skin			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hair Disorder			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Night Sweats			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Rash Maculo-Papular			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Rash Papular			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Rash Pruritic			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Skin Lesion			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Urticaria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Renal and urinary disorders Acute Kidney Injury subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Bladder Spasm subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Haematuria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Pollakiuria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Renal Colic subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Renal Failure subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Renal Vein Thrombosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Urinary Retention subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Arthritis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Back Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Groin Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Muscle Contracture			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Muscle Spasms			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Muscular Weakness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal Chest Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal Discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Neck Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Pain in Extremity			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Spinal Pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Furuncle			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Oral Herpes			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Respiratory Tract Infection			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Tooth Infection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Upper Respiratory Tract Infection			



subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Urinary Tract Infection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Hyponatraemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 September 2016	The overall reason for the amendment was to update toxicity and adverse event (AE) management in response to Health Authority request, to remove the subject-reported outcomes assessments (PRO), and to add timepoints for biomarker sample collection.
22 March 2017	The overall reason for the amendment was to allow subjects in Arm A (atezolizumab monotherapy) to cross over to Arm B (atezolizumab + daratumumab combination therapy) after confirmed disease progression. Combination therapy of daratumumab and atezolizumab may provide clinical benefit in non-small cell lung cancer (NSCLC) subjects who had disease progression on atezolizumab monotherapy. The combination of daratumumab with atezolizumab may lead to an improvement in clinical responses in NSCLC by enhancing the anti-tumor T cell responses facilitated by checkpoint inhibition. Therefore, subjects in Arm A with confirmed disease progression based on RECIST 1.1 may cross over to Arm B, provided all crossover eligibility criteria are met.
24 August 2017	The overall reason for the amendment was to allow for the enrollment of subjects in certain programmed-death ligand 1 (PD-L1) sub-groups to collect sufficient data to confirm clinical benefit.
26 February 2018	The overall reason for the amendment was to expand the Screening period for the informed consent and for PD-L1 testing, and to specify the PD-L1 score inclusion criterion. During its review of the study data at the initial interim analysis (40 evaluable subjects), the DMC determined that the study had enrolled a sufficient number of subjects with a PD-L1 score of tumor cells (TC0) and recommended continued enrollment only in subjects in the TC1-3 subgroups. In addition, the safety management guidelines for atezolizumab have been updated based on the current Investigator's Brochure.
19 April 2018	The overall reason for the amendment was to added a phase 1b Dara-SC cohort combined with a corticosteroid tapering regimen to the study protocol, to minimize the risk of IRRs and to improve the safety outcomes after daratumumab administration. An optional prescreening phase for archival testing to assess PD-L1 status was specified.
14 August 2018	The overall reason for the amendment was to initiated response to the third planned (Data monitoring committee) DMC review of safety data on 23 May 2018 (88 subjects) and added the DMC recommendation to stop further enrollment into the study, with discontinuation of daratumumab+atezolizumab treatment and specified that ongoing subjects could continue on atezolizumab monotherapy until the subject met one or more of the treatment discontinuation criteria.
04 October 2018	The overall reason for the amendment was to pursuant to the DMC recommendation to stop enrollment into the study, it was clarified that subjects who were deriving clinical benefit from atezolizumab monotherapy, but did not have access to commercial atezolizumab, could continue treatment according to the local regulatory approvals and standard of care guidelines. Data from efficacy and safety evaluations performed according to the local regulatory approvals and standard of care guidelines were no longer to be collected with the exception of serious adverse events that were to be reported and entered in the Sponsor safety repository.

Notes:

---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported